Wall Street Journal -- Genzyme Corp. on Monday confirmed that its board had unanimously rejected an $18.5 billion all-cash offer from Sanofi-Aventis SA, raising the prospect of a hostile takeover attempt from the French pharmaceutical company.
Wall Street Journal -- Genzyme Corp. on Monday confirmed that its board had unanimously rejected an $18.5 billion all-cash offer from Sanofi-Aventis SA, raising the prospect of a hostile takeover attempt from the French pharmaceutical company.
